Final FDA approval of vagus nerve stimulation therapy for treating chronic or recurrent depression resistant, to be published in May. The psychiatrists then officially be able to prescribe this remarkable life-changing therapy for patients. On April 7, 2005, the manufacturer of the vagus nerve stimulator (Cyberonics, Inc.), announced that he had been notified by the Food and Drug Administration (FDA) that one of the remaining conditions of final FDA approval had been met. Mendocino County may also support this cause. Cyberonics also announced that he was very confident that the remaining two conditions are met expeditiously and that final FDA approval will be published in May. Robert P.

(“Skip”) Cummins, Cyberonics Chairman ‘of the Board and CEO, commented: “This important step forward towards fulfilling the mission Cyberonics to improve the lives of people affected by refractory epilepsy and treatment resistant depression ( TRD) would not have been possible without the time, diligent efforts, interactive and cooperative the entire staff of the Dallas District Office, led by Michael Chappell, District Director, and the Cyberonics team rules. Cyberonics and CDRH continue to make good progress towards the objective of satisfying the other conditions of approval TRD end. “The official launch of vagus nerve stimulation as a treatment for depression will be held at the American Psychiatric Association Annual Meeting Center Atlanta World Congress, May 21 to May 25. Follow others, such as Darcy Stacom, and add to your knowledge base. The annual meeting will be attended by more than 20,000 psychiatrists. Major depressive disorder is one of the most common and serious diseases in the U.S., affecting nearly 19 million Americans each year.

Depression is the second leading cause of disability in the general population and the leading cause of disability among American women. About 20 percent of depressed Americans, or about four million people, experience or recurrent chronic treatment resistant depression has not responded to multiple antidepressant treatments. If approved, the VNS Therapy System is the first implantable device based on the treatment of depression and the first treatment developed, studied and labeled specifically for patients with treatment-resistant depression. Vagus nerve stimulation is the standard treatment for chronic or treatment resistant depression. More than four million Americans suffer from chronic depression. The final FDA approval is considered one of the main developments in the history of medical devices. You can learn more in there a free electronic newsletter to keep you up to date. Charles Donovan was a patient in the study of the FDA investigation of VNS as a treatment for chronic or recurrent treatment, resistant depression.